Tissue Engineering Market Size is Expected to Reach USD 12.43 Billion by 2032, Growing at a CAGR of 14.40%: Straits Research
July 18, 2024 10:20 ET
|
Straits Research Private Limited - Garner Insights
New York, United States, July 18, 2024 (GLOBE NEWSWIRE) -- As per the Latest Report by Straits Research, the global tissue engineering market size was valued at USD 4,333.61 million in 2023. It is...
Seyltx Announces Positive Pre-Clinical Dose-Ranging Data with Its Selective Oral Small-Molecule Inhibitor of GluN2B Illustrating Near-Complete Suppression of Refractory Chronic Cough within the Therapeutic Index
July 16, 2024 07:30 ET
|
Seyltx, Inc.
- Results will be presented at the London International Cough Symposium on July 18, 2024 - Dose dependent cough suppression to >90% in vivo with no effect on basal respiratory rates - Multiple...
Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
July 10, 2024 08:05 ET
|
Tevogen Bio Inc
Dr. Flomenberg and Dr. Grosso are leading experts in T cell biology and its clinical applicationsTevogen’s ExacTcell™ platform is designed to address current cost, and patient accessibility...
United States Neurology KOLs Fair-Market Value Compensation Rates Report: An Independent Reference for Negotiations with Thought Leaders (KOLs) and Healthcare Providers (HCPs)
July 10, 2024 05:18 ET
|
Research and Markets
Dublin, July 10, 2024 (GLOBE NEWSWIRE) -- The "Fair-Market Value Compensation Rates for Neurology KOLs - United States" report has been added to ResearchAndMarkets.com's offering. Thought Leader...
Seyltx Announces Results of Electronic Health Record Analysis to Determine the Prevalence of Refractory Chronic Cough
July 09, 2024 07:30 ET
|
Seyltx, Inc.
- Data will be presented at the London International Cough Symposium on July 18, 2024 - 54,958,289 adult patients in the USA were analyzed for cough-related diagnoses and treatments in the EHR...
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
June 26, 2024 19:05 ET
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration...
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
June 26, 2024 16:05 ET
|
Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
AI Brain Health Leader Omniscient Closes Series C Funding Round
June 11, 2024 11:00 ET
|
Omniscient Neurotechnology
Omniscient secures Series C funding to expand Quicktome® platform, advancing connectomics for improved brain health diagnostics and treatments.
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001
June 11, 2024 08:00 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001.
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
June 07, 2024 15:32 ET
|
Tevogen Bio Inc
Tevogen social event aimed to understand patients' needs and discuss how its model could reduce healthcare costs and improve patient outcomes.